Check 35,000+ stocks against 26 valuation models and 37 quality factors

Teleflex Incorporated (TFX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Teleflex Incorporated $45.54, price $122, upside -62.6%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US8793691069

Some data Sep 24, 2026

Teleflex Incorporated

TFX · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $45.54 · Strongly overvalued (−63%)

!Quality 51/100

!Mixed Growth (revenue 5y +3.3 %/yr)

!Loss-making · -47.4% net margin (TTM)

✓Moderate debt · generates free cash flow

·1.12% dividend yield

!Trails peers (3/14)

!Narrow moat 28/100

!Insider activity 40/100

!Evidence only medium, so the estimate is less certain

!Weak on dividend: 22 out of 100

26 models, one by oneBear $31.86 to bull $70.10 Growth analysisrevenue history, year by year Quality 51/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Teleflex Incorporated for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $99.79 – $407.21 · fair‑value band $31.86 – $70.10 · the $121.75 price screens above the $45.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Teleflex in your weekly email

Every Wednesday you see whether Teleflex is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Stock analysis

Teleflex Incorporated (TFX) currently trades at $121.75, while our model-based Fair Value estimate is $45.54, implying the stock looks roughly 167.4% overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of $59.33 per share, and 0 of the 15 models we run sit above the $121.75 price.

Bear case: the Earnings-Based group reads lowest at $6.22, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: $31.86 (bear) to $70.10 (bull), the price of $121.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Teleflex Incorporated reported revenue of $2.0B in FY2025 versus $2.8B in FY2021, a compound −8.2%/yr. Reported net income was −$906M in FY2025.

Key figures

Market cap $5.4B · P/S ratio 2.71 · EPS (TTM) $0.0500 · Dividend yield 1.1% · Net margin −45.4% · Return on equity 0.0% · Return on assets (EBIT) 5.8% · Operating margin 8.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 14% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −63%, TFX screens richer than that median.

Fair Value models

Bear $31.86 Fair Value $45.54 Bull $70.10

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $28.05 $59.33 $101.86 77

Growth DCF $30.07 $59.04 $96.78 76

5Y EBITDA Exit $36.31 $81.91 $132.58 72

All 15 models by family

DCF Models

FCF DCF $28.05 $59.33 $101.86 77

5Y Revenue Exit $11.03 $37.11 $68.71 68

5Y EBITDA Exit $36.31 $81.91 $132.58 72

10Y Revenue Exit $15.51 $39.62 $68.58 63

10Y EBITDA Exit $32.38 $69.17 $113.93 66

Earnings-Based

EPV n/a $6.22 $12.66 68

Dividend Discount

Gordon GGM $11.96 $19.45 $27.78 68

DDM Multi-Stage $11.96 $17.29 $22.98 67

Multiples

EV/EBIT $25.15 $49.71 $74.26 63

EV/EBITDA $54.30 $88.58 $122.85 66

EV/Revenue $4.06 $26.59 $49.13 47

Asset-Based

NCAV (Graham) $35.29 $47.29 $70.58 54

Growth DCF

Growth DCF $30.07 $59.04 $96.78 76

Rev-Margin DCF $11.03 $38.24 $67.54 68

Economic Profit

ROIC Compounder n/a $6.22 $12.66 68

Open the full fair value analysis →

Notify me when TFX reaches fair value

Put TFX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 50 · Market factors (momentum, volatility) 51

Profitability 8

Margins and returns on capital today

Quality Growth 23

Are margins and returns improving?

Cashflow 61

Earnings quality: real cash, not paper profit

Fin. Strength 43

Balance sheet, leverage, solvency risk

Investment 95

Disciplined investing over empire-building

Low Volatility 59

Calm price path (market factor)

Momentum 49

Price trend over the last 3–12 months (market factor)

52W Momentum 43

Distance to the 52-week high (market factor)

Net Issuance 100

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.7%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.3%

Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

16.7% (2020) → 12.8% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+16.7%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+6.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.0% a year for the price and +3.9% for the forecasts.

Forecast 2026 (sales)+14.8%

Forecast 2027 (sales)+4.9%

Projected 2028 (sales)+4.5%

Projected 2029 (sales)+4.2%

Projected 2030 (sales)+3.8%

TFX screens 167% overvalued. Compare with Intuitive Surgical, Inc →

Compare Teleflex Incorporated with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 205 stocks

Beats the industry median on 2/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 51 · Below median

Fair Value upside −63% · Bottom 25%

Profitability

Return on equity (TTM) 0% · Below median

Return on assets 2% · Below median

Net margin (TTM) −47% · Bottom 25%

Operating margin (TTM) 8% · Below median

Growth and dividend

Revenue growth 32% · Top 25%

Dividend yield (TTM) 1.1% · Below median

Balance sheet

Debt / equity 0.81× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 1.74× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (TTM) 2.56× · Pricier than median

P/FCF 22.2× · Pricier than median

EV/EBITDA 16.8× · Pricier than median

PEG 0.16× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 20

FUTURE (revenue growth)100 · sector 28

PAST (return on equity)0 · sector 25

HEALTH (low debt)59 · sector 96

DIVIDEND (yield)22 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$402.09	$353.38	−12%
EssilorLuxottica Société anonyme EL	€144.50	€158.95	+10%
Medline Inc MDLN	$34.43	$30.15	−12%
Becton, Dickinson and Company BDX	$183.00	$103.53	−43%
Alcon Inc ALC	$65.59	$39.78	−39%
ResMed Inc RMD	A$31.61	A$34.77	+10%
West Pharmaceutical Services, Inc WST	$371.09	$137.28	−63%
Sartorius Stedim Biotech S.A DIM	€206.40	€54.82	−73%
Straumann Holding STMN	CHF 97.86	CHF 45.50	−54%
Solventum Corporation SOLV	$88.75	$130.51	+47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Teleflex Incorporated · Fair Value
$45.54 −167%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/TFX" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Teleflex Incorporated · Fair Value</span><br><b style="font-size:20px">$45.54</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−167%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Teleflex Incorporated Fair Value". https://www.fairvalue-calculator.com/stock/TFX

Frequently asked questions

Is Teleflex Incorporated (TFX) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $45.54 versus a price of $121.75, about −63% upside (overvalued).

What is the fair value of TFX?

Our model-based fair value for Teleflex Incorporated is $45.54 (as of Sep 24, 2026), built from audited fundamentals. The current price: $121.75.

What is the quality score of TFX?

Teleflex Incorporated has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Teleflex Incorporated (TFX)?

Our model-based price target is the fair value of $45.54 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario $31.86, optimistic scenario $70.10. It is a calculation from audited fundamentals, not an analyst target.

What is the Teleflex Incorporated stock forecast for 2026?

Our models put fair value at $45.54, about −63% upside versus a price of $121.75 (overvalued). Cautious scenario $31.86, optimistic scenario $70.10. The calculation is refreshed regularly with new filings.

What is the revenue of Teleflex Incorporated (TFX)?

Teleflex Incorporated reported trailing-twelve-month revenue of about $2.1B (latest available figure, as of Sep 24, 2026).

Does Teleflex Incorporated pay a dividend?

Teleflex Incorporated currently shows a dividend yield of about 1.12% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Teleflex Incorporated (TFX)?

For today's price to be fair in a discounted-cash-flow model, Teleflex Incorporated would have to grow free cash flow by +16.7 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.7 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of TFX use?

Our models discount Teleflex Incorporated at 9.3 %: a base by market capitalisation (mid), damped by beta 0.82, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Teleflex Incorporated that is +16.7 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.

How much growth has Teleflex Incorporated (TFX) delivered so far?

Over the past 5 years revenue at Teleflex Incorporated grew -4.7 % a year. The price currently implies +16.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Teleflex Incorporated (TFX) growing?

The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into Teleflex Incorporated (+16.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Teleflex Incorporated (TFX)?

The free-cash-flow yield on the price is 4.51 %: that much free cash flow Teleflex Incorporated produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Teleflex Incorporated (TFX)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Teleflex Incorporated it is $45.54 per share (as of Sep 24, 2026), against a price of $121.75. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).

Is Teleflex Incorporated stock overvalued or undervalued in 2026?

As of Sep 24, 2026, TFX trades above its calculated fair value: price $121.75, fair value $45.54, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TFX?

No. The price is what the market pays today ($121.75); the fair value is what the company's own numbers justify ($45.54). For Teleflex Incorporated the two are $76.21 per share apart. That gap is exactly why we show both numbers side by side.

How much is Teleflex Incorporated worth?

The market values Teleflex Incorporated at about $5.4B (market capitalisation, as of Sep 24, 2026). Per share that is $121.75; our models calculate a fair value of $45.54 per share.

What do the bullish and bearish scenarios say about TFX?

Our models span a range for Teleflex Incorporated: cautious scenario $31.86, base $45.54, optimistic $70.10 per share (as of Sep 24, 2026, price $121.75). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of TFX?

The PEG ratio of Teleflex Incorporated is 0.16 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Teleflex Incorporated (TFX)?

Balance-sheet figures for Teleflex Incorporated (as of Sep 24, 2026): return on equity 0.0%, debt of 0.81 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.

How far is TFX from its 52-week high?

Teleflex Incorporated trades at $121.75, about 14% below its 52-week high of $142.05 and 22% above the low of $99.79 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $45.54 is for.

Which stocks are comparable to Teleflex Incorporated?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Teleflex Incorporated stock attractive at the current price?

The data as of Sep 24, 2026: price $121.75, calculated fair value $45.54 (−63%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TFX calculated?

We run Teleflex Incorporated through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $45.54, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Teleflex Incorporated itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Teleflex Incorporated (TFX)?

The closing price on Sep 23, 2026 was $121.75. Our model-based fair value is $45.54, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Teleflex Incorporated right now?

The price sits above even our optimistic bull case ($70.10). The favourable scenario is already priced in. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($31.86 to $70.10) leaves room in how you read the outcome.

Where does the earnings growth of Teleflex Incorporated (TFX) come from?

Earnings per share at Teleflex Incorporated grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.0 %, EBIT margin −4.9 %, tax rate −1.3 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Teleflex Incorporated

How large is the market capitalisation of Teleflex Incorporated (TFX)?

The market capitalisation of Teleflex Incorporated is $5.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Teleflex Incorporated (TFX)?

The price-to-sales ratio of Teleflex Incorporated is 2.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Teleflex Incorporated (TFX)?

Earnings per share at Teleflex Incorporated are $0.0500. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Teleflex Incorporated (TFX)?

The dividend yield of Teleflex Incorporated is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Teleflex Incorporated (TFX)?

The net margin of Teleflex Incorporated is −45.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Teleflex Incorporated (TFX)?

The return on equity (ROE) of Teleflex Incorporated is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Teleflex Incorporated (TFX)?

On an EBIT basis the return on assets of Teleflex Incorporated is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Teleflex Incorporated (TFX)?

The operating margin of Teleflex Incorporated is 8.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Teleflex Incorporated (TFX)?

Revenue at Teleflex Incorporated is growing +32.3% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Teleflex Incorporated (TFX)?

Earnings per share at Teleflex Incorporated are growing +64.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Teleflex Incorporated (TFX) carry?

The net debt of Teleflex Incorporated is $2.3B (fiscal year 2025, ≈ 9.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Teleflex Incorporated in the live analysis

One click puts Teleflex Incorporated on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.